fashion -WSS

fashion

author：hotspot 2025-09-27 19:37:35 - browse：75

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Patients' immediate access to test results puts radiologists in a bind

WSS

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Spinal cord stimulation reduces pain in amputees, study finds

STAT Readout Newsletter: Today in biotech, life science news

STAT letters to the editor on burnt

Wellcome Trust names Røttingen as its new CEO

Americans' trust in science, scientist continues decline: Report

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Peter Hotez and the public health issue of online harassment

STAT Readout: Today's biotech news includes Sana and Amylyx

Drug repurposing or repositioning? The language matters

Takeaways from AdvaMed, the largest medical devices conference

Continuity nursing helped my family in our darkest PICU moments

Akero's treatment for NASH falls short in cirrhosis study

Wildfire smoke exposes gaps in outdoor worker protections

Patients' immediate access to test results puts radiologists in a bind

Guidelines to prevent youth baseball injuries need more muscle

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

leisure time

Roche to buy Carmot Therapeutics, developer of obesity drugs

Life sciences deals on track to hit lowest point since 2017

How clinical AI models' predictive power can degrade over time

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Pharma patents targeted by Biden in move to slash drug prices

Readout LOUD podcast: Merger Mondays, Ozempic panic

entertainment

knowledge

entertainment

leisure time